Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03188848
Other study ID # BTP-20211-01
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date May 24, 2017
Est. completion date December 2019

Study information

Verified date July 2018
Source Betta Pharmaceuticals Co.,Ltd.
Contact Kexin Li, MD
Phone 13501238006
Email kexinli6202@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled, dose finding study evaluating the safety, pharmacokinetics and pharmacodynamics of subcutaneously injected BPI-3016 in Chinese healthy subjects.


Description:

BPI-3016 is a novel analogue of glucagon-like peptide-1 (GLP-1) that developed for the treatment of type 2 diabetes mellitus. This is a randomized, double-blind, placebo-controlled, dose finding study evaluating the safety, pharmacokinetics and pharmacodynamics of subcutaneously injected BPI-3016 in Chinese healthy subjects.


Recruitment information / eligibility

Status Recruiting
Enrollment 63
Est. completion date December 2019
Est. primary completion date July 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Healthy

- Subject's body mass index (BMI) is >=19 kilogram (kg)/meter(m)^2 and <=25 kg/m^2

- Male or female: if she is not pregnant (as confirmed by a test at screening and at other timepoints), not lactating, and at least one of the following conditions applies: a) cannot bear children OR b) agrees to follow contraception requirements defined in the protocol

- Capable of giving signed informed consent

Exclusion Criteria:

- Family history of multiple endocrine neoplasia, medullary carcinoma of the thyroid, or diabetes mellitus

- History of thymus disease, acute or chronic pancreatitis, or thyroid dysfunction

- History of gallstones, biliary motility dysfunction, cholecystitis or other gallbladder disease

- History of weight loss over 5% within 3 months of the study

- Abnormal blood pressure

- Abnormal blood routine, blood chemistry or test at screening

- Personal or family history of long QT syndrome, QT interval > 450 milliseconds (msec), or heart rate is >100 beats/min at Screening

- History of sensitivity or contraindication to any of the study medications or components thereof or a history of drug or other allergy

- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result, or a positive test for Human immunodeficiency virus (HIV) antibody

- A positive pre-study drug/alcohol screen

- The subject participated in a clinical trial and received an investigational product within 90 days

- History of drug or other allergy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
BPI-3016
Single-dose subcutaneous injection of BPI-3016
Placebo
Single-dose subcutaneous injection of placebo to match BPI-3016

Locations

Country Name City State
China Beijing Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Betta Pharmaceuticals Co.,Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of subjects with adverse events and serious adverse events An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgement will be categorized as SAE 1 month
Primary Plasma Concentrations of single-dose BPI-3016 The concentration of BPI-3016 following single-dose administration was estimated 15 days
Primary Tmax of single-dose BPI-3016 Time of the maximum observed plasma concentration (tmax) following single-dose administration of BPI-3016 was estimated 15 days
Primary AUC The area under the concentration-time (AUC) curve from time zero to the last quantifiable concentration (0-last) and AUC (0-inf) of BPI-3016 were measured 15 days
Primary T1/2 The half-life (t1/2) of single-dose BPI-3016 was measured 15 days
Secondary Change From Baseline in Fasting Plasma Glucose Fasting Plasma Glucose was measured pre-dose at baseline, day 2, day 3, day 4, day 5, and day 8 8 days
Secondary Change From Baseline in 2 hours postprandial blood glucose Fasting Plasma Glucose was measured pre-dose at baseline, day 2, day 3, day 4, day 5, and day 8 8 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02664883 - Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
Completed NCT05611281 - GS3-007a Oral Solution in Healthy Subjects Phase 1
Completed NCT03457480 - Text Messages in Preventing Tobacco Use in Young Adults N/A
Completed NCT05358756 - A Study of Bioavailability and Food Effect of SACT-1 and Edurant® Tablets in Healthy Adult Volunteers Phase 1
Completed NCT06037395 - Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety Between CT-P41 and US-licensed Prolia in Healthy Male Subjects Phase 1
Active, not recruiting NCT04032106 - HPV Vaccine Intervention for Young Sexual Minority Men N/A
Completed NCT04062955 - Effects of Alternative Healthy Eating Index-Based Diet on Inflammatory Markers and Breast Density in Healthy Participants N/A
Recruiting NCT03897270 - Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects N/A
Completed NCT01846520 - Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers N/A
Completed NCT02960100 - mHealth Intervention in Increasing HPV Vaccinations in College Students N/A
Completed NCT03698318 - Pharmacokinetics Assessing Bioavailability of Gingerols and Shogaols of Five Ginger Extracts N/A
Completed NCT05497635 - A Study of STSA-1002 in Healthy Subjects Phase 1
Active, not recruiting NCT03303846 - Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients N/A
Terminated NCT05559125 - A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects Phase 1
Completed NCT03584100 - Effect of Pneumatic Tourniquet on Arm Swelling After Lymph Node Removal N/A
Recruiting NCT05117385 - The Effect of the Consumption of 4 Botanical Extracts on Immunity in Healthy Adults (B-4-Immune) N/A
Active, not recruiting NCT05660720 - Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects Phase 1
Completed NCT01908920 - Osteopathic Manipulative Treatment Effects on High Frequency Parameters in Healthy Subjects N/A
Active, not recruiting NCT03491176 - Magnetic Resonance (MR) Imaging & Blood Biomarkers for Head and Neck Cancer N/A
Completed NCT03963323 - Glucosamine and Chondroitin in Gut in Preventing People From Inflammation Phase 1